Fines of nearly €150 million imposed on pharmaceutical company Lundbeck and a number of generic rivals by the European Commission have been upheld by the EU General Court. The Court's decisions are the first to find that pay-for-delay agreements breach EU antitrust rules
Unlock this content.
The content you are trying to view is exclusive to our subscribers.
Daniel Tarr explains why returning to his former firm could help him establish his personal brand, and predicts what’s on the horizon for AI litigation
A call to reinstate the European Commission's controversial SEP proposal and a trademark row involving Stanley cups were also among the top talking points